(PharmaNewsWire.Com, March 26, 2021 ) According to the new market research report AI in Genomics Market is projected to reach USD 1,671 million by 2025 from USD 202 million in 2020, at a CAGR of 52.7% between 2020 and 2025
The need to control drug development and discovery costs and time, increasing public and private investments in AI in genomics, and the adoption of AI solutions in precision medicine are driving the growth of this market. However, the lack of a skilled AI workforce and ambiguous regulatory guidelines for medical software are expected to restrain the Artificial Intelligence in Genomics Market growth during the forecast period.
The prominent players operating in the AI in Genomics market include IBM (US), Microsoft (US), NVIDIA Corporation (US), Deep Genomics (Canada), BenevolentAI (UK), Fabric Genomics Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch Inc. (US), Cambridge Cancer Genomics (UK), SOPHiA GENETICS (US), Data4Cure Inc. (US), PrecisionLife Ltd (UK), Genoox Ltd. (US), Lifebit (UK), Diploid (Belgium), FDNA Inc. (US), DNAnexus Inc. (US), Empiric Logic (Ireland), Engine Biosciences Pte. Ltd. (US), Illumina, Inc. (US), Genuity Science (US), and Trace Genomics, Inc. (US), among others. Players in this market focused on partnerships, collaborations, agreements, acquisitions, mergers, expansions, and product launches & approvals to expand their market presence between January 2018 and July 2020.
IBM (US)
IBM is one of the leading players in the AI in genomics market. The company provides IBM Watson, an AI platform, through its Cognitive Solutions segment. Watson is used by pharmaceutical companies and biotech & academic institutions to support new drug target identification and drug repurposing. IBM focuses on organic and inorganic growth strategies to improve its position in the AI in drug discovery and other emerging AI markets. Besides, partnerships and collaborations with AI solution providers/consumers remain an important aspect of its strategy to enhance its footprint in the Artificial Intelligence in Genomics Market.
NVIDIA (US)
NVIDIA is among the world leaders in the visual computing business. It has a well-established geographic footprint and deals with major OEMs/ODMs. The company continues to lead in the development of new products for AI. The company has significantly increased its R&D spending and aims to improve its gaming, machine learning, and other AI training algorithms. Furthermore, the company adopts different growth strategies, such as product launches, expansions, and partnerships, to maintain its leading position in the market. For instance, in September 2018, NVIDIA launched the NVIDIA Clara platform.
North America is the largest regional market for AI in Genomics in 2019
In 2019, North America accounted for the largest share of the AI in Genomics market, followed by Europe. The large share of North America can be attributed to the increasing research funding and government initiatives for promoting precision medicine in the US.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
